Table 4 Adverse events (any grade) with an incidence of ≥20%, safety population
Adverse event | Cohort 1: pertuzumab, trastuzumab, and vinorelbine N = 106 |
|---|---|
Any adverse event | 105 (99.1%) |
Diarrhea | 61 (57.5%) |
Neutropenia | 54 (50.9%) |
Nausea | 52 (49.1%) |
Asthenia | 42 (39.6%) |
Pyrexia | 37 (34.9%) |
Anemia | 36 (34.0%) |
Fatigue | 36 (34.0%) |
Constipation | 35 (33.0%) |
Vomiting | 34 (32.1%) |
Chills | 30 (28.3%) |
Alopecia | 27 (25.5%) |
Rash | 25 (23.6%) |
Leukopenia | 24 (22.6%) |
Decreased appetite | 23 (21.7%) |
Weight decreased | 22 (20.8%) |